A Randomized Phase I Study Comparing the Pharmacokinetics of HD201, a Trastuzumab Biosimilar, With European Union-sourced Herceptin.
Fiche publication
Date publication
mars 2018
Journal
Clinical therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier
Tous les auteurs :
Pivot X, Deslypere JP, Park LS, Kim MJ, Lee W, Lee J
Lien Pubmed
Résumé
This first-in-human study of HD201 was designed to evaluate the pharmacokinetic (PK) equivalence between this biosimilar candidate and trastuzumab sourced in the European Union (EU-trastuzumab)*.
Mots clés
Herceptin, biosimilars, breast cancer, pharmacokinetics, trastuzumab
Référence
Clin Ther. 2018 Mar;40(3):396-405.e4